Sano Makoto, Saotome Masao, Urushida Tsuyoshi, Katoh Hideki, Satoh Hiroshi, Ohnishi Kazunori, Hayashi Hideharu
Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine, Japan.
Intern Med. 2012;51(17):2337-40. doi: 10.2169/internalmedicine.51.7472. Epub 2012 Sep 1.
We present a case of pulmonary arterial hypertension (PAH), which is potentially related to treatment with dasatinib (Sprycel(®)). A 61-year-old woman, who had been treated with dasatinib for 27 months for chronic myeloid leukemia (CML), visited our hospital complaining of dyspnea. In right heart catheterization, her mean pulmonary arterial pressure was 35 mmHg. After other possible etiologies to cause PAH were excluded, the patient was diagnosed as a dasatinib-related PAH. As notified by U.S. Food and Drug Administration (FDA) in October 2011, we recommend routine cardiopulmonary evaluation before and during treatment with dasatinib in CML patients in terms of the adverse effects of PAH.
我们报告一例肺动脉高压（PAH）病例，其可能与达沙替尼（施达赛（Sprycel(®)））治疗有关。一名61岁女性，因慢性髓性白血病（CML）接受达沙替尼治疗27个月，因呼吸困难前来我院就诊。右心导管检查显示，其平均肺动脉压为35 mmHg。在排除其他可能导致PAH的病因后，该患者被诊断为与达沙替尼相关的PAH。正如美国食品药品监督管理局（FDA）在2011年10月所通报的，鉴于PAH的不良反应，我们建议在CML患者使用达沙替尼治疗前及治疗期间进行常规心肺评估。
